Damien Reynolds Appointed Chief Capital Markets Officer
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/14/15 -- THC BioMed Intl Ltd. ("THC") (FRANKFURT: TFHC)(CSE: THC)(OTC PINK: THCBF) is pleased to announce it has appointed Damien Reynolds as Chief Capital Markets Officer. Mr. Reynolds brings over 25 years of Global Capital markets experience including M&A, start up incubation, strategic investments and has been directly involved in raising significant venture capital. Mr. Reynolds will be instrumental in helping the Company achieve its goal of global growth.
The Company welcomes Damien to the team and looks forward to building a successful international life sciences company.
The Company has granted 1,000,000 incentive stock options to Mr. Reynolds, 500,000 at a price of $0.10 per share and 500,000 at a price of $0.15 per share with an exercise period of two years. The options vest over the course of one year, with 25% vesting on the date of grant and 25% every 4 months following the date of grant.
THC''s vision is to be on the leading edge of scientific research and development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.
Please visit our website for a more detailed description of our business and services available. .
Forward-Looking Information:
This press release contains certain "forward-looking information" within the meaning of applicable securities law. The forward looking statements include that (i) Mr. Reynolds will be instrumental in helping the Company achieve its goal of global growth and (ii) As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. These statements are based on expectations and assumptions made by the management of THC at the date the information is provided, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing THC and its business and affairs, readers should refer to THC''s Listing Statement, Financial Statements and its Management''s Discussion and Analysis on .
Contacts:
THC BioMed Intl Ltd.
John Miller
President and CEO
604 682-1643
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.07.2015 - 06:00 Uhr
Sprache: Deutsch
News-ID 1372032
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 162 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Damien Reynolds Appointed Chief Capital Markets Officer
"
steht unter der journalistisch-redaktionellen Verantwortung von
THC BioMed Intl Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
